{ "run": { "id": "cmnr14tei05nup658znn412md", "region": "US", "assetId": "cmnr14tdv05nop65817bf8h63", "ticker": "PFE", "snapshotId": "cmnr14te805nqp658idje1q75", "promptTemplateId": "cmnqt07si0005lm3jzpxuu1ux", "createdAt": "2026-04-09T05:21:34.935Z", "promptTemplate": { "id": "cmnqt07si0005lm3jzpxuu1ux", "name": "Oficial 08.apr.2026", "version": 1 }, "snapshot": { "id": "cmnr14te805nqp658idje1q75", "assetId": "cmnr14tdv05nop65817bf8h63", "asOf": "2026-04-08T20:03:09.000Z", "snapshot": { "asOf": "2026-04-08T20:03:09.000Z", "quote": { "asOf": "2026-04-08T20:03:09.000Z", "open": null, "price": 27.47, "dayLow": 26.965, "volume": 33768782, "dayHigh": 27.49, "currency": "USD", "prevClose": 27.1, "week52Low": 20.92, "week52High": 28.75 }, "fundamentals": { "pe": 18.1751824817518, "beta": 0.40103984476066, "epsTTM": 1.37, "fcfTTM": 4188000000, "growth": { "epsYoy": -0.03521126760563368, "revenueYoy": -0.01647099501783834 }, "sector": "Pharmaceutical Preparations", "margins": { "net": 0.1241790376963518, "gross": 0.1308266351331916, "operating": null }, "website": "https://www.pfizer.com/", "industry": "Pharmaceutical", "pegRatio": -5.16175182481754, "ebitdaTTM": 21722000000, "forwardPe": 8.38383838383838, "marketCap": 138000000000, "totalCash": 1142000000, "totalDebt": 64795000000, "debtEquity": 0.749283038068366, "quickRatio": 0.370187107938568, "revenueTTM": 62579000000, "companyName": "PFIZER INC", "priceToBook": 1.63073120138289, "currentRatio": 1.159906986805105, "dividendYield": 0.0691062684664401, "returnOnAssets": 0.03733186010760953, "returnOnEquity": 0.0898630833988621, "analystOpinions": null, "businessSummary": "Pfizer Inc. (/ˈfaɪzər/ FY-zər) is an American multinational pharmaceutical and biotechnology corporation headquartered at The Spiral in Manhattan, New York City. Founded in 1849 in New York by German entrepreneurs Charles Pfizer (1824–1906) and Charles F. Erhart (1821–1891), Pfizer is one of the oldest pharmaceutical companies in North America.", "enterpriseValue": 205159700000, "analystTargetLow": null, "analystTargetHigh": null, "analystTargetMean": null, "fullTimeEmployees": 75000, "sharesOutstanding": 5686267431, "enterpriseToEbitda": 9.444788693490471, "analystTargetMedian": null, "enterpriseToRevenue": 3.278411288131801, "operatingCashflowTTM": 11704000000, "analystRecommendationKey": null } }, "createdAt": "2026-04-09T05:21:34.929Z" }, "results": [ { "id": "cmnr14tek05nwp658hzqquwex", "runId": "cmnr14tei05nup658znn412md", "modelId": "anthropic", "status": "SUCCESS", "rawOutput": "{\"model\":\"ai-equity-research-v1\",\"as_of\":\"2026-04-08T20:03:09.000Z\",\"ticker\":\"PFE\",\"currency\":\"USD\",\"current_price\":27.47,\"target_price_6m\":29.5,\"target_price_12m\":31.0,\"recommendation\":\"BUY\",\"confidence\":0.62,\"thesis_bullets\":[\"Forward PE of 8.4x implies substantial earnings inflection ahead\",\"~6.9% dividend yield provides downside cushion and total-return support\",\"Seagen acquisition bolsters oncology pipeline with blockbuster potential\",\"High net debt ($63.6B) constrains financial flexibility and buybacks\",\"Post-COVID revenue base stabilizing with modest growth trajectory\"],\"key_drivers\":[{\"driver\":\"Oncology revenue ramp from Seagen portfolio (Padcev, Adcetris)\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"COVID product revenue normalization and Paxlovid tail\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Cost synergies from Seagen integration ($4B target)\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Pipeline catalysts (obesity, RSV, oncology readouts)\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Elevated debt load limiting capital allocation optionality\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Attractive dividend yield anchoring valuation floor\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Patent cliff risk on legacy portfolio (Eliquis LOE ~2028)\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Low beta (0.40) defensive positioning in volatile macro\",\"impact\":\"LOW\",\"direction\":\"POS\"}],\"risks\":[\"Seagen integration execution risk or slower-than-expected oncology ramp\",\"Eliquis patent expiry and generic erosion starting late 2020s\",\"Pipeline clinical trial failures in key indications\",\"Regulatory or pricing headwinds (IRA drug negotiation impact)\",\"Rising interest expense on $65B debt burden pressuring FCF\",\"Dividend sustainability concerns if earnings miss forward estimates\"],\"assumptions\":{\"revenue_cagr_3y\":0.04,\"ebit_margin_target\":0.28,\"wacc\":0.085,\"terminal_multiple\":10.0},\"scenarios\":{\"bear\":{\"target_price\":23.0,\"prob\":0.2,\"notes\":\"Pipeline setbacks, Seagen underperformance, multiple compresses to 7x forward.\"},\"base\":{\"target_price\":31.0,\"prob\":0.55,\"notes\":\"Earnings inflect toward ~$3.20 forward EPS; 9.5-10x forward PE applied.\"},\"bull\":{\"target_price\":37.0,\"prob\":0.25,\"notes\":\"Oncology acceleration plus pipeline wins drive re-rating to 11-12x forward PE.\"}},\"method_notes\":\"Valuation anchored on forward PE (snapshot fwd PE 8.4x implies ~$3.28 fwd EPS). Applied 9.5x base-case multiple for 12M target of ~$31. Cross-checked with EV/EBITDA (9.4x current, modest expansion warranted). Total return including ~6.9% dividend yield supports BUY. High debt and patent cliffs cap confidence at 0.62. Sell-side consensus noted but not used as numeric input. Not investment advice.\"}", "parsedJson": { "as_of": "2026-04-08T20:03:09.000Z", "model": "ai-equity-research-v1", "risks": [ "Seagen integration execution risk or slower-than-expected oncology ramp", "Eliquis patent expiry and generic erosion starting late 2020s", "Pipeline clinical trial failures in key indications", "Regulatory or pricing headwinds (IRA drug negotiation impact)", "Rising interest expense on $65B debt burden pressuring FCF", "Dividend sustainability concerns if earnings miss forward estimates" ], "ticker": "PFE", "currency": "USD", "scenarios": { "base": { "prob": 0.55, "notes": "Earnings inflect toward ~$3.20 forward EPS; 9.5-10x forward PE applied.", "target_price": 31 }, "bear": { "prob": 0.2, "notes": "Pipeline setbacks, Seagen underperformance, multiple compresses to 7x forward.", "target_price": 23 }, "bull": { "prob": 0.25, "notes": "Oncology acceleration plus pipeline wins drive re-rating to 11-12x forward PE.", "target_price": 37 } }, "confidence": 0.62, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": 0.04, "terminal_multiple": 10, "ebit_margin_target": 0.28 }, "key_drivers": [ { "driver": "Oncology revenue ramp from Seagen portfolio (Padcev, Adcetris)", "impact": "HIGH", "direction": "POS" }, { "driver": "COVID product revenue normalization and Paxlovid tail", "impact": "MED", "direction": "NEG" }, { "driver": "Cost synergies from Seagen integration ($4B target)", "impact": "HIGH", "direction": "POS" }, { "driver": "Pipeline catalysts (obesity, RSV, oncology readouts)", "impact": "HIGH", "direction": "POS" }, { "driver": "Elevated debt load limiting capital allocation optionality", "impact": "MED", "direction": "NEG" }, { "driver": "Attractive dividend yield anchoring valuation floor", "impact": "MED", "direction": "POS" }, { "driver": "Patent cliff risk on legacy portfolio (Eliquis LOE ~2028)", "impact": "HIGH", "direction": "NEG" }, { "driver": "Low beta (0.40) defensive positioning in volatile macro", "impact": "LOW", "direction": "POS" } ], "method_notes": "Valuation anchored on forward PE (snapshot fwd PE 8.4x implies ~$3.28 fwd EPS). Applied 9.5x base-case multiple for 12M target of ~$31. Cross-checked with EV/EBITDA (9.4x current, modest expansion warranted). Total return including ~6.9% dividend yield supports BUY. High debt and patent cliffs cap confidence at 0.62. Sell-side consensus noted but not used as numeric input. Not investment advice.", "current_price": 27.47, "recommendation": "BUY", "thesis_bullets": [ "Forward PE of 8.4x implies substantial earnings inflection ahead", "~6.9% dividend yield provides downside cushion and total-return support", "Seagen acquisition bolsters oncology pipeline with blockbuster potential", "High net debt ($63.6B) constrains financial flexibility and buybacks", "Post-COVID revenue base stabilizing with modest growth trajectory" ], "target_price_6m": 29.5, "target_price_12m": 31 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "anthropic", "webSearch": { "enabled": false, "maxToolCalls": 2, "disabledReason": null }, "pauseTurns": 0, "stopReason": "end_turn" }, "sanityIssues": [] }, "latencyMs": 36206, "createdAt": "2026-04-09T05:21:34.935Z", "usage": { "inputTokens": 3610, "outputTokens": 1578, "costUsd": 0.0575 } }, { "id": "cmnr14tel05nzp658tqfzcq2n", "runId": "cmnr14tei05nup658znn412md", "modelId": "deepseek.reasoner", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"AI_Research_Model\",\n \"as_of\": \"2026-04-08T20:03:09.000Z\",\n \"ticker\": \"PFE\",\n \"currency\": \"USD\",\n \"current_price\": 27.47,\n \"target_price_6m\": 28.5,\n \"target_price_12m\": 30.0,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.65,\n \"thesis_bullets\": [\n \"Revenue and EPS are declining year-over-year.\",\n \"Forward P/E is low, indicating potential undervaluation.\",\n \"High dividend yield offers income stability.\",\n \"Elevated debt levels increase financial risk.\",\n \"New drug pipeline could drive future growth.\"\n ],\n \"key_drivers\": [\n {\"driver\": \"Revenue Growth\", \"impact\": \"MED\", \"direction\": \"NEG\"},\n {\"driver\": \"EPS Growth\", \"impact\": \"MED\", \"direction\": \"NEG\"},\n {\"driver\": \"Forward P/E Ratio\", \"impact\": \"HIGH\", \"direction\": \"POS\"},\n {\"driver\": \"Dividend Yield\", \"impact\": \"LOW\", \"direction\": \"POS\"},\n {\"driver\": \"Debt Level\", \"impact\": \"MED\", \"direction\": \"NEG\"},\n {\"driver\": \"New Drug Pipeline\", \"impact\": \"HIGH\", \"direction\": \"POS\"},\n {\"driver\": \"Cost Management\", \"impact\": \"MED\", \"direction\": \"POS\"},\n {\"driver\": \"Regulatory Environment\", \"impact\": \"MED\", \"direction\": \"NEG\"}\n ],\n \"risks\": [\n \"Further decline in revenue and earnings\",\n \"Intensifying competition in pharmaceutical markets\",\n \"Regulatory hurdles for new product approvals\",\n \"High interest expenses due to debt\",\n \"Macroeconomic factors affecting healthcare demand\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.02,\n \"ebit_margin_target\": 0.15,\n \"wacc\": 0.075,\n \"terminal_multiple\": 10.0\n },\n \"scenarios\": {\n \"bear\": {\"target_price\": 25.0, \"prob\": 0.2, \"notes\": \"Continued revenue and margin pressures.\"},\n \"base\": {\"target_price\": 30.0, \"prob\": 0.6, \"notes\": \"Modest recovery in earnings and stable margins.\"},\n \"bull\": {\"target_price\": 35.0, \"prob\": 0.2, \"notes\": \"Strong pipeline execution and cost efficiencies.\"}\n },\n \"method_notes\": \"Valuation based on DCF with assumed 2% revenue CAGR, 15% EBIT margin, 7.5% WACC, 10x terminal multiple. BUY recommendation due to 9% upside in base case. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:03:09.000Z", "model": "AI_Research_Model", "risks": [ "Further decline in revenue and earnings", "Intensifying competition in pharmaceutical markets", "Regulatory hurdles for new product approvals", "High interest expenses due to debt", "Macroeconomic factors affecting healthcare demand" ], "ticker": "PFE", "currency": "USD", "scenarios": { "base": { "prob": 0.6, "notes": "Modest recovery in earnings and stable margins.", "target_price": 30 }, "bear": { "prob": 0.2, "notes": "Continued revenue and margin pressures.", "target_price": 25 }, "bull": { "prob": 0.2, "notes": "Strong pipeline execution and cost efficiencies.", "target_price": 35 } }, "confidence": 0.65, "assumptions": { "wacc": 0.075, "revenue_cagr_3y": 0.02, "terminal_multiple": 10, "ebit_margin_target": 0.15 }, "key_drivers": [ { "driver": "Revenue Growth", "impact": "MED", "direction": "NEG" }, { "driver": "EPS Growth", "impact": "MED", "direction": "NEG" }, { "driver": "Forward P/E Ratio", "impact": "HIGH", "direction": "POS" }, { "driver": "Dividend Yield", "impact": "LOW", "direction": "POS" }, { "driver": "Debt Level", "impact": "MED", "direction": "NEG" }, { "driver": "New Drug Pipeline", "impact": "HIGH", "direction": "POS" }, { "driver": "Cost Management", "impact": "MED", "direction": "POS" }, { "driver": "Regulatory Environment", "impact": "MED", "direction": "NEG" } ], "method_notes": "Valuation based on DCF with assumed 2% revenue CAGR, 15% EBIT margin, 7.5% WACC, 10x terminal multiple. BUY recommendation due to 9% upside in base case. Not investment advice.", "current_price": 27.47, "recommendation": "BUY", "thesis_bullets": [ "Revenue and EPS are declining year-over-year.", "Forward P/E is low, indicating potential undervaluation.", "High dividend yield offers income stability.", "Elevated debt levels increase financial risk.", "New drug pipeline could drive future growth." ], "target_price_6m": 28.5, "target_price_12m": 30 }, "errorsJson": { "attempts": [], "providerMeta": { "endpoint": "https://api.deepseek.com/v1/chat/completions", "provider": "deepseek", "webSearch": { "enabled": false, "supported": false }, "responseFormat": "json_object" }, "sanityIssues": [] }, "latencyMs": 370, "createdAt": "2026-04-09T05:21:34.935Z", "usage": { "inputTokens": 2112, "outputTokens": 3898, "costUsd": 0.002229 } }, { "id": "cmnr14tek05nxp658fxa3dz6c", "runId": "cmnr14tei05nup658znn412md", "modelId": "gemini.3-pro", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"AI Equity Analyst\",\n \"as_of\": \"2026-04-08T20:03:09.000Z\",\n \"ticker\": \"PFE\",\n \"currency\": \"USD\",\n \"current_price\": 27.47,\n \"target_price_6m\": 29.00,\n \"target_price_12m\": 31.00,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.65,\n \"thesis_bullets\": [\n \"Forward P/E of 8.4x prices in excessive pessimism regarding post-COVID revenue cliffs.\",\n \"Seagen acquisition bolsters oncology pipeline, offsetting patent cliffs expected later this decade.\",\n \"High 6.9% dividend yield provides strong income, though FCF coverage remains a near-term concern.\",\n \"Cost-cutting initiatives aim to restore operating margins and support debt deleveraging efforts.\",\n \"Pipeline execution in obesity and RSV vaccines is critical for long-term multiple expansion.\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Seagen Integration\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"COVID Franchise Decline\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Dividend Sustainability\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Cost Realignment Program\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"GLP-1/Obesity Pipeline\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Debt Deleveraging\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Eliquis/Ibrance LOE\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n }\n ],\n \"risks\": [\n \"Free cash flow currently insufficient to comfortably cover the high dividend payout.\",\n \"Failure to successfully commercialize Seagen's oncology assets.\",\n \"Intense competition in the obesity and RSV vaccine markets.\",\n \"Upcoming loss of exclusivity (LOE) for key blockbusters like Eliquis.\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.02,\n \"ebit_margin_target\": 0.28,\n \"wacc\": 0.075,\n \"terminal_multiple\": 10.0\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 22.00,\n \"prob\": 0.3,\n \"notes\": \"Pipeline failures and debt burden force a dividend cut, triggering a severe re-rating.\"\n },\n \"base\": {\n \"target_price\": 31.00,\n \"prob\": 0.5,\n \"notes\": \"Earnings stabilize at $3.20/share, dividend is maintained, and Seagen integration proceeds smoothly.\"\n },\n \"bull\": {\n \"target_price\": 38.00,\n \"prob\": 0.2,\n \"notes\": \"Breakthroughs in obesity pipeline and rapid oncology growth drive multiple expansion to 12x forward P/E.\"\n }\n },\n \"method_notes\": \"Valuation based on a 9.5x target multiple on expected forward EPS of $3.27, supported by a DCF model (WACC 7.5%, 2% terminal growth). The 12.8% upside warrants a BUY rating, though high leverage and FCF dividend coverage require monitoring. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:03:09.000Z", "model": "AI Equity Analyst", "risks": [ "Free cash flow currently insufficient to comfortably cover the high dividend payout.", "Failure to successfully commercialize Seagen's oncology assets.", "Intense competition in the obesity and RSV vaccine markets.", "Upcoming loss of exclusivity (LOE) for key blockbusters like Eliquis." ], "ticker": "PFE", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Earnings stabilize at $3.20/share, dividend is maintained, and Seagen integration proceeds smoothly.", "target_price": 31 }, "bear": { "prob": 0.3, "notes": "Pipeline failures and debt burden force a dividend cut, triggering a severe re-rating.", "target_price": 22 }, "bull": { "prob": 0.2, "notes": "Breakthroughs in obesity pipeline and rapid oncology growth drive multiple expansion to 12x forward P/E.", "target_price": 38 } }, "confidence": 0.65, "assumptions": { "wacc": 0.075, "revenue_cagr_3y": 0.02, "terminal_multiple": 10, "ebit_margin_target": 0.28 }, "key_drivers": [ { "driver": "Seagen Integration", "impact": "HIGH", "direction": "POS" }, { "driver": "COVID Franchise Decline", "impact": "HIGH", "direction": "NEG" }, { "driver": "Dividend Sustainability", "impact": "HIGH", "direction": "POS" }, { "driver": "Cost Realignment Program", "impact": "MED", "direction": "POS" }, { "driver": "GLP-1/Obesity Pipeline", "impact": "MED", "direction": "POS" }, { "driver": "Debt Deleveraging", "impact": "MED", "direction": "NEG" }, { "driver": "Eliquis/Ibrance LOE", "impact": "HIGH", "direction": "NEG" } ], "method_notes": "Valuation based on a 9.5x target multiple on expected forward EPS of $3.27, supported by a DCF model (WACC 7.5%, 2% terminal growth). The 12.8% upside warrants a BUY rating, though high leverage and FCF dividend coverage require monitoring. Not investment advice.", "current_price": 27.47, "recommendation": "BUY", "thesis_bullets": [ "Forward P/E of 8.4x prices in excessive pessimism regarding post-COVID revenue cliffs.", "Seagen acquisition bolsters oncology pipeline, offsetting patent cliffs expected later this decade.", "High 6.9% dividend yield provides strong income, though FCF coverage remains a near-term concern.", "Cost-cutting initiatives aim to restore operating margins and support debt deleveraging efforts.", "Pipeline execution in obesity and RSV vaccines is critical for long-term multiple expansion." ], "target_price_6m": 29, "target_price_12m": 31 }, "errorsJson": { "attempts": [], "providerMeta": { "model": "gemini-3-pro-preview", "provider": "gemini", "webSearch": { "used": false, "allowed": false, "enabled": false, "requested": false, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 25062, "createdAt": "2026-04-09T05:21:34.935Z", "usage": { "inputTokens": 2472, "outputTokens": 907, "costUsd": 0.015828 } }, { "id": "cmnr14tek05nvp6584uvhlz6f", "runId": "cmnr14tei05nup658znn412md", "modelId": "openai.gpt-5.4", "status": "SUCCESS", "rawOutput": "{\"model\":\"o3\",\"as_of\":\"2026-04-08T20:03:09.000Z\",\"ticker\":\"PFE\",\"currency\":\"USD\",\"current_price\":27.47,\"target_price_6m\":29.6,\"target_price_12m\":31,\"recommendation\":\"BUY\",\"confidence\":0.63,\"thesis_bullets\":[\"Forward P/E implies muted recovery already priced in.\",\"6.9% dividend supports total return at current levels.\",\"Seagen adds oncology scale and pipeline optionality.\",\"Cost actions can lift margins after COVID reset.\",\"Debt and patent expiries limit rerating upside.\"],\"key_drivers\":[{\"driver\":\"Seagen integration and synergies\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Oncology launch uptake\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Cost reduction execution\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"COVID product revenue normalization\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Patent expiry erosion\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Net debt reduction\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Clinical and regulatory wins\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Pricing and reimbursement pressure\",\"impact\":\"MED\",\"direction\":\"NEG\"}],\"risks\":[\"Larger-than-expected patent-loss erosion\",\"Seagen integration or trial setbacks\",\"Dividend pressure if cash conversion weak\",\"US pricing reform compresses margins\",\"Litigation or regulatory surprises\"],\"assumptions\":{\"revenue_cagr_3y\":0.03,\"ebit_margin_target\":0.29,\"wacc\":0.085,\"terminal_multiple\":9.5},\"scenarios\":{\"bear\":{\"target_price\":23.5,\"prob\":0.25,\"notes\":\"LOE pressure and weak launches keep earnings compressed.\"},\"base\":{\"target_price\":31,\"prob\":0.5,\"notes\":\"Modest growth, margin recovery and stable valuation multiple.\"},\"bull\":{\"target_price\":37,\"prob\":0.25,\"notes\":\"Oncology outperforms and deleveraging drives rerating.\"}},\"method_notes\":\"Targets use snapshot quote/fundamentals and a blended forward earnings, EV/EBITDA and FCF-yield framework; no sell-side targets used. Snapshot fields were kept authoritative. BUY reflects ~13% 12M upside with medium uncertainty from leverage and patent cliffs; not investment advice.\"}", "parsedJson": { "as_of": "2026-04-08T20:03:09.000Z", "model": "o3", "risks": [ "Larger-than-expected patent-loss erosion", "Seagen integration or trial setbacks", "Dividend pressure if cash conversion weak", "US pricing reform compresses margins", "Litigation or regulatory surprises" ], "ticker": "PFE", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Modest growth, margin recovery and stable valuation multiple.", "target_price": 31 }, "bear": { "prob": 0.25, "notes": "LOE pressure and weak launches keep earnings compressed.", "target_price": 23.5 }, "bull": { "prob": 0.25, "notes": "Oncology outperforms and deleveraging drives rerating.", "target_price": 37 } }, "confidence": 0.63, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": 0.03, "terminal_multiple": 9.5, "ebit_margin_target": 0.29 }, "key_drivers": [ { "driver": "Seagen integration and synergies", "impact": "HIGH", "direction": "POS" }, { "driver": "Oncology launch uptake", "impact": "HIGH", "direction": "POS" }, { "driver": "Cost reduction execution", "impact": "HIGH", "direction": "POS" }, { "driver": "COVID product revenue normalization", "impact": "MED", "direction": "NEG" }, { "driver": "Patent expiry erosion", "impact": "HIGH", "direction": "NEG" }, { "driver": "Net debt reduction", "impact": "MED", "direction": "POS" }, { "driver": "Clinical and regulatory wins", "impact": "MED", "direction": "POS" }, { "driver": "Pricing and reimbursement pressure", "impact": "MED", "direction": "NEG" } ], "method_notes": "Targets use snapshot quote/fundamentals and a blended forward earnings, EV/EBITDA and FCF-yield framework; no sell-side targets used. Snapshot fields were kept authoritative. BUY reflects ~13% 12M upside with medium uncertainty from leverage and patent cliffs; not investment advice.", "current_price": 27.47, "recommendation": "BUY", "thesis_bullets": [ "Forward P/E implies muted recovery already priced in.", "6.9% dividend supports total return at current levels.", "Seagen adds oncology scale and pipeline optionality.", "Cost actions can lift margins after COVID reset.", "Debt and patent expiries limit rerating upside." ], "target_price_6m": 29.6, "target_price_12m": 31 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "openai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "resp_05b10f4e36a1c0b40069d75c4ec1ec81908540636c5a5ff80b", "reasoningEffort": "medium", "structuredOutputs": { "used": true, "requested": true, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 35389, "createdAt": "2026-04-09T05:21:34.935Z", "usage": { "inputTokens": 2383, "outputTokens": 2012, "costUsd": 0.032338 } }, { "id": "cmnr14tel05nyp65851j6sqfn", "runId": "cmnr14tei05nup658znn412md", "modelId": "xai.grok-4.20-reasoning", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"AI Equity Analyst\",\n \"as_of\": \"2026-04-08T20:03:09.000Z\",\n \"ticker\": \"PFE\",\n \"currency\": \"USD\",\n \"current_price\": 27.47,\n \"target_price_6m\": 29.5,\n \"target_price_12m\": 32,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.62,\n \"thesis_bullets\": [\n \"Declining COVID sales pressure near-term revenues.\",\n \"Strong oncology pipeline drives future growth potential.\",\n \"Generous 6.9% dividend yield supports returns.\",\n \"High debt from acquisitions adds financial risk.\",\n \"Low forward PE of 8.4x signals undervaluation.\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Oncology drug approvals\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"COVID revenue normalization\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Cost optimization programs\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Patent expirations\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Dividend consistency\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"M&A integration\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Clinical trial outcomes\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Interest costs on debt\",\n \"impact\": \"LOW\",\n \"direction\": \"NEG\"\n }\n ],\n \"risks\": [\n \"Pipeline clinical failures\",\n \"Accelerated revenue loss from patents\",\n \"Rising interest expense burden\",\n \"Regulatory delays on new drugs\",\n \"Intense competitor pricing pressure\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.04,\n \"ebit_margin_target\": 0.25,\n \"wacc\": 0.09,\n \"terminal_multiple\": 12\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 23.5,\n \"prob\": 0.35,\n \"notes\": \"Pipeline delays and margin pressure lead to de-rating.\"\n },\n \"base\": {\n \"target_price\": 32,\n \"prob\": 0.45,\n \"notes\": \"Moderate pipeline success and cost cuts stabilize earnings.\"\n },\n \"bull\": {\n \"target_price\": 39,\n \"prob\": 0.2,\n \"notes\": \"Multiple blockbuster approvals accelerate revenue growth.\"\n }\n },\n \"method_notes\": \"DCF using 4% revenue CAGR, 25% EBIT margin, 9% WACC and 12x terminal. 16% expected return supports BUY. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:03:09.000Z", "model": "AI Equity Analyst", "risks": [ "Pipeline clinical failures", "Accelerated revenue loss from patents", "Rising interest expense burden", "Regulatory delays on new drugs", "Intense competitor pricing pressure" ], "ticker": "PFE", "currency": "USD", "scenarios": { "base": { "prob": 0.45, "notes": "Moderate pipeline success and cost cuts stabilize earnings.", "target_price": 32 }, "bear": { "prob": 0.35, "notes": "Pipeline delays and margin pressure lead to de-rating.", "target_price": 23.5 }, "bull": { "prob": 0.2, "notes": "Multiple blockbuster approvals accelerate revenue growth.", "target_price": 39 } }, "confidence": 0.62, "assumptions": { "wacc": 0.09, "revenue_cagr_3y": 0.04, "terminal_multiple": 12, "ebit_margin_target": 0.25 }, "key_drivers": [ { "driver": "Oncology drug approvals", "impact": "HIGH", "direction": "POS" }, { "driver": "COVID revenue normalization", "impact": "HIGH", "direction": "NEG" }, { "driver": "Cost optimization programs", "impact": "MED", "direction": "POS" }, { "driver": "Patent expirations", "impact": "HIGH", "direction": "NEG" }, { "driver": "Dividend consistency", "impact": "MED", "direction": "POS" }, { "driver": "M&A integration", "impact": "MED", "direction": "POS" }, { "driver": "Clinical trial outcomes", "impact": "MED", "direction": "NEG" }, { "driver": "Interest costs on debt", "impact": "LOW", "direction": "NEG" } ], "method_notes": "DCF using 4% revenue CAGR, 25% EBIT margin, 9% WACC and 12x terminal. 16% expected return supports BUY. Not investment advice.", "current_price": 27.47, "recommendation": "BUY", "thesis_bullets": [ "Declining COVID sales pressure near-term revenues.", "Strong oncology pipeline drives future growth potential.", "Generous 6.9% dividend yield supports returns.", "High debt from acquisitions adds financial risk.", "Low forward PE of 8.4x signals undervaluation." ], "target_price_6m": 29.5, "target_price_12m": 32 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "xai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "c20ef389-f92f-96cd-acd5-91f6eb6859d3", "usedFallbackChatCompletions": false }, "sanityIssues": [] }, "latencyMs": 20813, "createdAt": "2026-04-09T05:21:34.935Z", "usage": { "inputTokens": 2724, "outputTokens": 3337, "costUsd": 0.058227 } } ] } }